Fangyi Zhao

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Dantrolene Inhibition of Ryanodine Receptor Ca2+Release Channels

Fangyi Zhao, Pin Li, S. R. Wayne Chen et al. · Journal of Biological Chemistry · 2001 · 321 citations · Full text

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena et al. · Arthritis & Rheumatology · 2018 · 224 citations · Full text

Dose correspondence between olanzapine long-acting injection and oral olanzapine

Holland C. Detke, Fangyi Zhao, Parag Garhyan et al. · International Clinical Psychopharmacology · 2010 · 184 citations

Olanzapine Long-acting Injection, Oral Olanzapine, Psychiatry +13